SCHEDULE: Halpern Family Discloses 5.6% Stake in Ernexa Therapeutics

John and Katherine Halpern have filed an amended Schedule 13G reporting a 5.6% beneficial ownership stake in Ernexa Therapeutics Inc.

Summary

• John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, report a combined beneficial ownership of 66,751 shares of Ernexa Therapeutics Inc. common stock.
• The reported stake represents 5.6% of the company's outstanding common stock.
• The holdings include 46,445 shares held directly by the Trust, 306 shares issuable via pre-funded warrants, and 20,000 shares issuable via common warrants.
• The share count reflects the impact of a 1-for-15 reverse stock split on June 10, 2025, and a 1-for-25 reverse stock split on May 4, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure regarding ownership changes, with no direct impact on the company's operational performance.

Positives

• The reporting persons maintain a significant long-term interest in the company, evidenced by their continued holding of both common stock and warrants.

Negatives

• The company has undergone two significant reverse stock splits within a year, which often indicates past downward pressure on the share price.

Risks

• The company's capital structure is subject to volatility due to the potential exercise of warrants.
• The reliance on reverse stock splits to manage share count may reflect underlying challenges in maintaining market valuation.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, focusing instead on the disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that frequent reverse stock splits in the biotechnology sector are often utilized by micro-cap companies to maintain compliance with exchange listing requirements, though they can signal dilution or historical valuation struggles.

Comparison to Industry Standards

• The use of multiple reverse stock splits within a 12-month period is aggressive compared to standard corporate governance practices in the broader pharmaceutical industry.

Stakeholder Impact

• Shareholders should note the concentration of ownership and the impact of recent reverse stock splits on share liquidity.

Next Steps

• Continued monitoring of the company's share count and potential warrant exercises.

Key Dates

Keywords

Ernexa Therapeutics, Schedule 13G, Beneficial Ownership, Reverse Stock Split, Biotech, Halpern Trust